deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02238626

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) (IBU-ALS-1201)

A Single-center, Randomized, Double-blind, Placebo-controlled, 6-month Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With (ALS)

Sponsor: MediciNova

Conditions Amyotrophic Lateral Sclerosis
Interventions MN-166 Placebo (for MN-166) riluzole
Updated 13 times since 2017 Last updated: Oct 7, 2021 Started: Sep 30, 2014 Primary completion: Aug 31, 2017 Completion: Dec 31, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02238626, this PHASE2 trial focuses on Amyotrophic Lateral Sclerosis and remains completed. Sponsored by MediciNova, it has been updated 13 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~May 2019 · 5 months · monthly snapshot~May 2019 – ~Jun 2020 · 13 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Dec 2021 · 9 months · monthly snapshot~Dec 2021 – ~May 2022 · 5 months · monthly snapshot~May 2022 – ~Jul 2024 · 26 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. May 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2021 — May 2022 [monthly]

    Completed PHASE2

  5. Mar 2021 — Dec 2021 [monthly]

    Completed PHASE2

▶ Show 8 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Completed PHASE2

  2. Jun 2020 — Jan 2021 [monthly]

    Completed PHASE2

  3. May 2019 — Jun 2020 [monthly]

    Completed PHASE2

  4. Dec 2018 — May 2019 [monthly]

    Completed PHASE2

  5. Jun 2018 — Dec 2018 [monthly]

    Completed PHASE2

  6. Feb 2018 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  7. Feb 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • MediciNova
  • Wake Forest University Health Sciences
Data source: MediciNova

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations